Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05142696 · ClinicalTrials.gov registry record · Phase 1

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

A Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
24
Enrollment target
20
Study locations

NCT05142696 is a Phase 1 study of Extensive-stage Small-cell Lung Cancer that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 24 participants, below the 175-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05142696, a Phase 1 study of Extensive-stage Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
20
Study locations

Study Summary

This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Atezolizumab
  • DRUG [177Lu]Lu-DOTA-TATE
  • DRUG [68Ga]Ga-DOTA-TATE
  • OTHER Carboplatin
  • OTHER Etoposide

Study Locations (20)

Other

  • Novartis Investigative Site - Vienna
  • Novartis Investigative Site - Beijing
  • Novartis Investigative Site - Shanghai
  • Novartis Investigative Site - Olomouc
  • Novartis Investigative Site - Bron
  • Novartis Investigative Site - Lille
  • Novartis Investigative Site - Marseille
  • Novartis Investigative Site - Montpellier

District of Columbia

  • Georgetown University Lombardi Cancer Center - Washington D.C.

Florida

  • Advent Health Cancer Institute - Orlando

Georgia

  • University Cancer and Blood Center LLC - Athens

Kentucky

  • University of Kentucky - Lexington

Missouri

  • St. Louis University - St Louis

New Jersey

  • Hackensack Meridian Health - Edison

Ohio

  • University Hospitals Of Cleveland - Cleveland

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2022-07-13
Est. Completion 2029-03-23
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05142696

The ClinicalTrials.gov registry entry for NCT05142696 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.

NCT05142696 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, District of Columbia, Florida.

Frequently Asked Questions

What is clinical trial NCT05142696 about?

NCT05142696 is a clinical study titled "A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab". This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The stu...

What is the current status of trial NCT05142696?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-07-13. Estimated completion is 2029-03-23.

What conditions does trial NCT05142696 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT05142696?

The interventions under investigation include: Atezolizumab (DRUG), [177Lu]Lu-DOTA-TATE (DRUG), [68Ga]Ga-DOTA-TATE (DRUG), Carboplatin (OTHER), Etoposide (OTHER).

Who is sponsoring clinical trial NCT05142696?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05142696 being conducted?

This trial has 20 study locations across District of Columbia, Florida, Georgia, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Extensive-stage Small-cell Lung Cancer

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.